检索结果 - Brian Gadbaw

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Ruxolitinib for the Treatment of Patients with Steroid-Refractory GVHD: An Introduction to the REACH Trials

    Ruxolitinib for the Treatment of Patients with Steroid-Refractory GVHD: An Introduction to the REACH Trials 由 Madan Jagasia, Robert Zeiser, Michael Arbushites, Patricia Delaite, Brian Gadbaw, Nikolas von Bubnoff

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

    Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study 由 Alì Taher, Zeynep Karakaş, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Aurelio Maggio, Stefano Rivella, Norbert Hollaender, Bruyère Mahuzier, Brian Gadbaw, Yeşim Aydınok

    出版 2017
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  3. 3
    Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

    Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study 由 Alessandro M. Vannucchi, Srđan Verstovšek, Paola Guglielmelli, Martin Grießhammer, Timothy C. Burn, Ahmad Naim, Dilan Paranagama, Mahtab Marker, Brian Gadbaw, Jean‐Jacques Kiladjian

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Phase II trial of hu14.18-IL2 for patients with metastatic melanoma

    Phase II trial of hu14.18-IL2 for patients with metastatic melanoma 由 Mark R. Albertini, Jacquelyn A. Hank, Brian Gadbaw, Jordan Kostlevy, Jennifer Haldeman, Heidi Schalch, Jacek Gan, KyungMann Kim, Jens C. Eickhoff, Stephen D. Gillies, Paul M. Sondel

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

    Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues 由 Edward M. Wolin, Barbara Jarząb, Barbro Eriksson, Thomas Walter, Christos Toumpanakis, Michael A. Morse, Paola Tomassetti, Matthias M. Weber, David R. Fogelman, John Ramage, Donald Poon, Brian Gadbaw, Li Jiang, Janice L. Pasieka, Abakar Mahamat, Fredrik Swahn, John Newell‐Price, Wasat Mansoor, Kjell Öberg

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

    Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy 由 David Delgado, Jacquelyn A. Hank, Jill Kolesar, David Lorentzen, Jacek Gan, Songwon Seo, KyungMann Kim, Suzanne Shusterman, Stephen D. Gillies, Ralph A. Reisfeld, Richard K. Yang, Brian Gadbaw, Kenneth DeSantes, Wendy B. London, Robert C. Seeger, John M. Maris, Paul M. Sondel

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

    Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study 由 Suzanne Shusterman, Wendy B. London, Stephen D. Gillies, Jacquelyn A. Hank, Stephan D. Voss, Robert C. Seeger, C. Patrick Reynolds, Jennifer Kimball, Mark R. Albertini, Barrett Wagner, Jacek Gan, Jens C. Eickhoff, Kenneth DeSantes, Susan L. Cohn, Toby T. Hecht, Brian Gadbaw, Ralph A. Reisfeld, John M. Maris, Paul M. Sondel

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: